Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Lebanese Health Ministry: 1 woman martyred, 11 wounded in Israeli strike on residential apartment in Nabatieh, South Lebanon.
Al Mayadeen's correspondent: Four civilians injured in Israeli strike that targeted house in Nabatieh al-Fawqa, South Lebanon.
Al Mayadeen's correspondent in South Lebanon: Israeli warplanes launch strikes on regions of al-Mahmoudiyah, al-Khardali
Al Mayadeen's correspondent in South Lebanon: Israeli aircraft execute series of strikes in Kfar Tibnit, South Lebanon.
Iranian ambassador in Beijing to Al Mayadeen: We hope that Europe and the US give up their illegal actions and authoritarian hegemony.
Al Mayadeen's correspondent: Israeli shelling targets displaced persons' tent in Al-Mawasi, Khan Younis, casualties were reported
IOF storm Jalazone camp, north of Al Bireh city in the occupied West Bank
Israeli media: A severe incident reported in Gaza some time ago
Israeli media: Military evacuation helicopters are transporting injured soldiers from Khan Younis
Israeli media: A security incident has been reported in Khan Younis, southern Gaza Strip

FDA approval of Alzheimer's drug Aduhelm ‘rife with irregularities’

  • By Al Mayadeen English
  • Source: Agencies
  • 30 Dec 2022 10:24
3 Min Read

This comes against the backdrop of criticism as the FDA is expected to decide on approving another drug for treating the disease in January.

  • x
  • Probe: Alzheimer’s drug approval ‘rife with irregularities’
    Probe: Alzheimer’s drug approval ‘rife with irregularities’

Sources reported on Friday that the 2021 FDA's approval of an Alzheimer's drug called Aduhelm was "rife with irregularities" as an 18-month congressional investigation issued on Thursday found an "atypical collaboration" between FDA regulators and Aduhelm manufacturer, Biogen. 

According to the probe, investigators found that the company intended to "make history" when it set an "unjustifiably high" initial yearly price of $56,000 for the drug.

This comes against the backdrop of criticism as the FDA is expected to decide on approving another drug for treating the disease in January.

The report also found that there was an unusually high amount of phone exchanges between company officials and FDA delegates.

It also revealed that the company and the agency spent months preparing a report that did not account for substantial disagreement within the FDA about how to handle Aduhelm.

The report called on the agency to take "swift action" to make sure that any future approvals aren't met with "the same doubts about the integrity of FDA’s review."

Both the company and the FDA issued statements on Thursday to defend Aduhelm's approval process.

Biogen knew Aduhelm would dramatically affect Medicare. If just 250,000 patients got the drug, it would account for more than 25% of the Part B budget. If Aduhelm reached its full potential, it would cost taxpayers upward of $70 billion. pic.twitter.com/B2y46UrE95

— Damian Garde (@damiangarde) December 29, 2022

Related News

Alzheimer's drug approval optimistic amid promising results

UN report reveals cocaine in upward trend, meth market expands

Read more: Canada going as far as possible abuse with MAiD, hitting brakes needed

The FDA approved Aduhelm in 2021 under accelerated approval over the objections of its independent scientific advisors who felt the data failed to prove the drug's benefit to patients.

The company had reportedly halted two studies after results suggested that the drug wasn't giving the desired effects: slowing Alzheimer's deteriorating process. 

The FDA said the drug was efficient on the grounds that it reduced a buildup of plaque in the brain.

But three of the agency's advisors resigned in protest of these claims and the agency's then-acting chief was called for questioning. 

Medicare eventually declined to fund the drug, even after the yearly price was reduced to $28,000.

In a statement Thursday, FDA said its "decision to approve Aduhelm was based on our scientific evaluation of the data contained in the application, which is described in the approval materials. ... That said, the agency has already started implementing changes consistent with the Committee's recommendations."

On Biogen's part, it said "Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm,” but that it “stands by the integrity of the actions we have taken."

Read more: Scientists develop new blood test for Alzheimer’s disease

  • Drug
  • Alzheimer's Disease

Most Read

Iranian President Masoud Pezeshkian attends a protest following the US attacks on nuclear sites in Iran, in Tehran, Iran, Sunday, June 22, 2025. (AP)

Iran declares victory as ceasefire forces Israeli retreat

  • Politics
  • 24 Jun 2025
Israeli workers survey the site where a missile launched from Iran struck in Haifa on Sunday, June 22, 2025. (AP)

True Promise 3, wave 20: 40 missiles launched, Kheibar-Shekan in first

  • Politics
  • 22 Jun 2025
Iran launches strikes on Israeli targets, despite alleged ceasefire

Iran victorious as ceasefire with 'Israel' takes effect

  • Politics
  • 24 Jun 2025
Iranian worshippers carry their country's flags in a protest to condemn Israeli attacks on multiple cities across Iran, after the Friday prayers ceremony in Tehran, Iran, Friday, June 20, 2025. (AP)

Iran warns of NPT withdrawal, Strait of Hormuz closure after US attack

  • Politics
  • 22 Jun 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
French far-right leader Marine Le Pen delivers her speech during the French far-right party national rally near the parliament in Paris, Sunday, April 6, 2025. (AP Photo/Michel Euler)
Politics

US aide proposed funding Le Pen's legal fight, sparking uproar

People whose names were left out in the National Register of Citizens (NRC) draft fill their forms to file appeals near a NRC center on the outskirts of Gauhati, India, Monday, Aug. 13, 2018. (AP Photo/Anupam Nath)
Politics

India accused of illegal Muslim deportations to Bangladesh

Palestinians children mourn over the body of their father, Mohammed Ghaben, who was killed while heading to an aid distribution hub, at the morgue of the Shifa Hospital in Gaza City, Wednesday, June 18, 2025. (AP)
Politics

IOF troops admit to killing starving Palestinians: Israeli media

The commander of the Quds Force's Palestine Unit, Brigadier General Mohammad Said Izadi (Illustrated by Mahdi Rtail for Al Mayadeen English)
Politics

Who was Mohammad Said Izadi, head of the Quds Force's Palestine Unit?

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS